Current Report Articles
Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Drug Trial (July 24, 2020) – In a controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with COVID-19, patients were randomly assigned to receive oral or intravenous Dexamethasone at a dose of 6 mg once daily for up to 10 days or to receive usual care alone. Published July 17 in the New England Journal of Medicine, preliminary results show that in patients hospitalized with COVID-19, the use of Dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
--Karen Braman